High	O
molecular	O
weight	O
PEGylation	O
of	O
human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
at	O
position	O
22	O
improves	O
stability	O
and	O
reduces	O
food	I:C0231353
intake	I:C0231353
in	O
mice	O
.	O

High	O
molecular	O
weight	O
PEGylation	O
of	O
human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
at	O
position	O
22	O
improves	O
stability	O
and	O
reduces	B:C0231353
food	I:C0231353
intake	I:C0231353
in	O
mice	O
.	O

High	O
molecular	O
weight	O
PEGylation	O
of	O
human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
at	O
position	O
22	O
improves	O
stability	O
and	O
reduces	O
food	I:C0231353
intake	I:C0231353
in	O
mice	B:C0025929
.	O

Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	O
appetite	I:C0858274
and	O
food	O
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	I:C0025517
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	O
appetite	I:C0858274
and	O
food	O
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	I:C0025517
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	B:C0858274
appetite	I:C0858274
and	O
food	O
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	I:C0025517
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	O
appetite	I:C0858274
and	O
food	B:C0013470
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	O
disorders	I:C0025517
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	O
appetite	I:C0858274
and	O
food	O
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	B:C0028754
and	O
associated	O
metabolic	O
disorders	I:C0025517
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
(	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
)	O
is	O
known	O
to	O
suppress	O
appetite	I:C0858274
and	O
food	O
intake	I:C0013470
,	O
thereby	O
representing	O
a	O
potential	O
therapeutic	O
approach	O
against	O
obesity	O
and	O
associated	O
metabolic	B:C0025517
disorders	I:C0025517
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	O
glycols	I:C0032483
(	O
polyethylene	O
glycols	I:C0032483
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	O
activity	I:C0243095
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	B:C0032483
glycols	I:C0032483
(	O
polyethylene	O
glycols	I:C0032483
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	O
activity	I:C0243095
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	O
glycols	I:C0032483
(	O
polyethylene	B:C0032483
glycols	I:C0032483
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	O
activity	I:C0243095
.	O

The	O
aim	O
of	O
this	O
study	O
was	O
to	O
improve	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
stability	O
by	O
covalent	O
PEGylation	O
with	O
diverse	O
molecular	O
weight	O
polyethylene	O
glycols	I:C0032483
(	O
polyethylene	O
glycols	I:C0032483
)	O
at	O
two	O
positions	O
using	O
promising	O
lead	O
structures	O
while	O
maintaining	O
target	B:C0243095
activity	I:C0243095
.	O

Modified	O
peptides	O
were	O
synthesized	O
by	O
combined	O
solid	O
-	O
phase	O
and	O
solution	B:C1518961
-	I:C1518961
phase	I:C1518961
peptide	I:C1518961
synthesis	I:C1518961
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	B:C0014597
epithelial	I:C0014597
cells	I:C0014597
and	O
isolated	O
human	O
colonic	I:C0227349
mucosa	I:C0227349
as	O
well	O
as	O
receptor	O
-	I:C0040669
transfected	I:C0040669
artificial	O
cell	I:C0007600
lines	I:C0007600
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	O
epithelial	I:C0014597
cells	I:C0014597
and	O
isolated	O
human	B:C0227349
colonic	I:C0227349
mucosa	I:C0227349
as	O
well	O
as	O
receptor	O
-	I:C0040669
transfected	I:C0040669
artificial	O
cell	I:C0007600
lines	I:C0007600
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	O
epithelial	I:C0014597
cells	I:C0014597
and	O
isolated	O
human	O
colonic	I:C0227349
mucosa	I:C0227349
as	O
well	O
as	O
receptor	B:C0040669
-	I:C0040669
transfected	I:C0040669
artificial	O
cell	I:C0007600
lines	I:C0007600
.	O

Their	O
potency	O
was	O
investigated	O
in	O
constitutively	O
expressing	O
human	O
epithelial	I:C0014597
cells	I:C0014597
and	O
isolated	O
human	O
colonic	I:C0227349
mucosa	I:C0227349
as	O
well	O
as	O
receptor	O
-	I:C0040669
transfected	I:C0040669
artificial	B:C0007600
cell	I:C0007600
lines	I:C0007600
.	O

Human	B:C0304926
blood	I:C0304926
plasma	I:C0304926
and	O
porcine	O
liver	I:C0023884
homogenates	O
were	O
used	O
to	O
examine	O
the	O
in	O
vitro	O
stability	O
of	O
the	O
analogues	O
.	O

Human	O
blood	I:C0304926
plasma	I:C0304926
and	O
porcine	B:C0023884
liver	I:C0023884
homogenates	O
were	O
used	O
to	O
examine	O
the	O
in	O
vitro	O
stability	O
of	O
the	O
analogues	O
.	O

The	O
most	O
promising	O
variants	O
were	O
injected	O
s.c.	O
in	O
C57BL	B:C1521751
/	I:C1521751
6JRj	I:C1521751
mice	I:C1521751
to	O
monitor	O
fasting	O
-	I:C0086311
induced	I:C0086311
food	I:C0086311
intake	I:C0086311
and	O
bioavailability	O
.	O

The	O
most	O
promising	O
variants	O
were	O
injected	O
s.c.	O
in	O
C57BL	O
/	I:C1521751
6JRj	I:C1521751
mice	I:C1521751
to	O
monitor	O
fasting	B:C0086311
-	I:C0086311
induced	I:C0086311
food	I:C0086311
intake	I:C0086311
and	O
bioavailability	O
.	O

In	O
human	B:C0014609
epithelia	I:C0014609
and	O
colonic	O
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	I:C0032483
.	O

In	O
human	O
epithelia	I:C0014609
and	O
colonic	B:C0227349
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	I:C0032483
.	O

In	O
human	O
epithelia	I:C0014609
and	O
colonic	O
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	I:C0032483
.	O

In	O
human	O
epithelia	I:C0014609
and	O
colonic	O
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	B:C0030956
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	O
size	I:C0032483
.	O

In	O
human	O
epithelia	I:C0014609
and	O
colonic	O
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	B:C0030956
was	O
related	O
to	O
PEG	O
size	I:C0032483
.	O

In	O
human	O
epithelia	I:C0014609
and	O
colonic	O
mucosal	I:C0227349
preparations	O
,	O
activity	O
of	O
the	O
modified	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
peptides	O
depended	O
on	O
the	O
core	O
sequence	O
and	O
latency	O
of	O
the	O
peptides	O
was	O
related	O
to	O
PEG	B:C0032483
size	I:C0032483
.	O

Peptides	B:C0030956
modified	O
with	O
a	O
22	O
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	I:C0304926
and	O
on	O
incubation	O
with	O
liver	O
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Peptides	O
modified	O
with	O
a	O
22	B:C0032483
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	I:C0304926
and	O
on	O
incubation	O
with	O
liver	O
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	B:C0032483
)	O
remained	O
intact	O
in	O
blood	O
plasma	I:C0304926
and	O
on	O
incubation	O
with	O
liver	O
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	B:C0304926
plasma	I:C0304926
and	O
on	O
incubation	O
with	O
liver	O
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	I:C0304926
and	O
on	O
incubation	B:C1439852
with	O
liver	O
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Peptides	O
modified	O
with	O
a	O
22	O
kDa	I:C0032483
PEG	I:C0032483
(	O
PEG22	O
)	O
remained	O
intact	O
in	O
blood	O
plasma	I:C0304926
and	O
on	O
incubation	O
with	O
liver	B:C0023884
homogenates	I:C0023884
for	O
more	O
than	O
96	O
h	O
.	O

Finally	O
,	O
hPP2	B:C0030298
-	I:C0030298
36	I:C0030298
,	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
]	O
hPP2	O
-36	I:C0030298
and	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
,	O
Q(	O
34	O
)	O
]	O

Finally	O
,	O
hPP2	O
-	I:C0030298
36	I:C0030298
,	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
]	O
hPP2	B:C0030298
-36	I:C0030298
and	O
[	O
K	O
(	O
22	O
)	O
(	O
PEG22	O
)	O
,	O
Q(	O
34	O
)	O
]	O

Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
reduced	O
cumulative	O
food	O
intake	I:C0013470
in	O
mice	O
over	O
16	O
h	O
after	O
s.c.	O
administration	O
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
reduced	O
cumulative	O
food	B:C0013470
intake	I:C0013470
in	O
mice	O
over	O
16	O
h	O
after	O
s.c.	O
administration	O
.	O

Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
reduced	O
cumulative	O
food	O
intake	I:C0013470
in	O
mice	B:C0025929
over	O
16	O
h	O
after	O
s.c.	O
administration	O
.	O

Modification	O
with	O
PEG22	B:C0032483
at	O
position	O
22	O
stabilizes	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
while	O
extending	O
its	O
biological	O
activities	I:C2267218
and	O
could	O
be	O
used	O
in	O
drug	O
development	I:C0872152
prospectively	O
.	O

Modification	O
with	O
PEG22	O
at	O
position	O
22	O
stabilizes	O
Human	B:C0030298
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
while	O
extending	O
its	O
biological	O
activities	I:C2267218
and	O
could	O
be	O
used	O
in	O
drug	O
development	I:C0872152
prospectively	O
.	O

Modification	O
with	O
PEG22	O
at	O
position	O
22	O
stabilizes	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
while	O
extending	O
its	O
biological	B:C2267218
activities	I:C2267218
and	O
could	O
be	O
used	O
in	O
drug	O
development	I:C0872152
prospectively	O
.	O

Modification	O
with	O
PEG22	O
at	O
position	O
22	O
stabilizes	O
Human	O
pancreatic	I:C0030298
polypeptide	I:C0030298
significantly	O
while	O
extending	O
its	O
biological	O
activities	I:C2267218
and	O
could	O
be	O
used	O
in	O
drug	B:C0872152
development	I:C0872152
prospectively	O
.	O

